Copyright Reports & Markets. All rights reserved.

Global Targeted Drugs for Multiple Myeloma Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Targeted Drugs for Multiple Myeloma Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Immunomodulator
      • 1.4.3 Proteasome Inhibitors
      • 1.4.4 Histone Deacetylase Inhibitors (HDACI)
      • 1.4.5 Monoclonal Antibody
      • 1.4.6 Other
    • 1.5 Market by Application
      • 1.5.1 Global Targeted Drugs for Multiple Myeloma Market Share by Application (2014-2025)
      • 1.5.2 Hospital
      • 1.5.3 Drug Center
      • 1.5.4 Clinic
      • 1.5.5 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Targeted Drugs for Multiple Myeloma Market Size
    • 2.2 Targeted Drugs for Multiple Myeloma Growth Trends by Regions
      • 2.2.1 Targeted Drugs for Multiple Myeloma Market Size by Regions (2014-2025)
      • 2.2.2 Targeted Drugs for Multiple Myeloma Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Targeted Drugs for Multiple Myeloma Market Size by by Players
      • 3.1.1 Global Targeted Drugs for Multiple Myeloma Revenue by by Players (2014-2019)
      • 3.1.2 Global Targeted Drugs for Multiple Myeloma Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Targeted Drugs for Multiple Myeloma Market Concentration Ratio (CR5 and HHI)
    • 3.2 Targeted Drugs for Multiple Myeloma Key Players Head office and Area Served
    • 3.3 Key Players Targeted Drugs for Multiple Myeloma Product/Solution/Service
    • 3.4 Date of Enter into Targeted Drugs for Multiple Myeloma Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Targeted Drugs for Multiple Myeloma Market Size by Type (2014-2019)
    • 4.2 Global Targeted Drugs for Multiple Myeloma Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Targeted Drugs for Multiple Myeloma Market Size (2014-2019)
    • 5.2 Targeted Drugs for Multiple Myeloma Key Players in United States
    • 5.3 United States Targeted Drugs for Multiple Myeloma Market Size by Type
    • 5.4 United States Targeted Drugs for Multiple Myeloma Market Size by Application

    6 Europe

    • 6.1 Europe Targeted Drugs for Multiple Myeloma Market Size (2014-2019)
    • 6.2 Targeted Drugs for Multiple Myeloma Key Players in Europe
    • 6.3 Europe Targeted Drugs for Multiple Myeloma Market Size by Type
    • 6.4 Europe Targeted Drugs for Multiple Myeloma Market Size by Application

    7 China

    • 7.1 China Targeted Drugs for Multiple Myeloma Market Size (2014-2019)
    • 7.2 Targeted Drugs for Multiple Myeloma Key Players in China
    • 7.3 China Targeted Drugs for Multiple Myeloma Market Size by Type
    • 7.4 China Targeted Drugs for Multiple Myeloma Market Size by Application

    8 Japan

    • 8.1 Japan Targeted Drugs for Multiple Myeloma Market Size (2014-2019)
    • 8.2 Targeted Drugs for Multiple Myeloma Key Players in Japan
    • 8.3 Japan Targeted Drugs for Multiple Myeloma Market Size by Type
    • 8.4 Japan Targeted Drugs for Multiple Myeloma Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Targeted Drugs for Multiple Myeloma Market Size (2014-2019)
    • 9.2 Targeted Drugs for Multiple Myeloma Key Players in Southeast Asia
    • 9.3 Southeast Asia Targeted Drugs for Multiple Myeloma Market Size by Type
    • 9.4 Southeast Asia Targeted Drugs for Multiple Myeloma Market Size by Application

    10 India

    • 10.1 India Targeted Drugs for Multiple Myeloma Market Size (2014-2019)
    • 10.2 Targeted Drugs for Multiple Myeloma Key Players in India
    • 10.3 India Targeted Drugs for Multiple Myeloma Market Size by Type
    • 10.4 India Targeted Drugs for Multiple Myeloma Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Targeted Drugs for Multiple Myeloma Market Size (2014-2019)
    • 11.2 Targeted Drugs for Multiple Myeloma Key Players in Central & South America
    • 11.3 Central & South America Targeted Drugs for Multiple Myeloma Market Size by Type
    • 11.4 Central & South America Targeted Drugs for Multiple Myeloma Market Size by Application

    12 International Players Profiles

    • 12.1 Celgene
      • 12.1.1 Celgene Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Targeted Drugs for Multiple Myeloma Introduction
      • 12.1.4 Celgene Revenue in Targeted Drugs for Multiple Myeloma Business (2014-2019)
      • 12.1.5 Celgene Recent Development
    • 12.2 SL Pharma
      • 12.2.1 SL Pharma Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Targeted Drugs for Multiple Myeloma Introduction
      • 12.2.4 SL Pharma Revenue in Targeted Drugs for Multiple Myeloma Business (2014-2019)
      • 12.2.5 SL Pharma Recent Development
    • 12.3 Natco Pharma
      • 12.3.1 Natco Pharma Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Targeted Drugs for Multiple Myeloma Introduction
      • 12.3.4 Natco Pharma Revenue in Targeted Drugs for Multiple Myeloma Business (2014-2019)
      • 12.3.5 Natco Pharma Recent Development
    • 12.4 Intas Pharmaceuticals
      • 12.4.1 Intas Pharmaceuticals Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Targeted Drugs for Multiple Myeloma Introduction
      • 12.4.4 Intas Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2014-2019)
      • 12.4.5 Intas Pharmaceuticals Recent Development
    • 12.5 Indiabulls Pharmaceutical
      • 12.5.1 Indiabulls Pharmaceutical Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Targeted Drugs for Multiple Myeloma Introduction
      • 12.5.4 Indiabulls Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2014-2019)
      • 12.5.5 Indiabulls Pharmaceutical Recent Development
    • 12.6 Cipla
      • 12.6.1 Cipla Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Targeted Drugs for Multiple Myeloma Introduction
      • 12.6.4 Cipla Revenue in Targeted Drugs for Multiple Myeloma Business (2014-2019)
      • 12.6.5 Cipla Recent Development
    • 12.7 Glenmark Pharmaceuticals
      • 12.7.1 Glenmark Pharmaceuticals Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Targeted Drugs for Multiple Myeloma Introduction
      • 12.7.4 Glenmark Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2014-2019)
      • 12.7.5 Glenmark Pharmaceuticals Recent Development
    • 12.8 Dr Reddy's Laboratories
      • 12.8.1 Dr Reddy's Laboratories Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Targeted Drugs for Multiple Myeloma Introduction
      • 12.8.4 Dr Reddy's Laboratories Revenue in Targeted Drugs for Multiple Myeloma Business (2014-2019)
      • 12.8.5 Dr Reddy's Laboratories Recent Development
    • 12.9 Qilu Pharmaceutical
      • 12.9.1 Qilu Pharmaceutical Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Targeted Drugs for Multiple Myeloma Introduction
      • 12.9.4 Qilu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2014-2019)
      • 12.9.5 Qilu Pharmaceutical Recent Development
    • 12.10 Chia Tai-Tianqing
      • 12.10.1 Chia Tai-Tianqing Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Targeted Drugs for Multiple Myeloma Introduction
      • 12.10.4 Chia Tai-Tianqing Revenue in Targeted Drugs for Multiple Myeloma Business (2014-2019)
      • 12.10.5 Chia Tai-Tianqing Recent Development
    • 12.11 Hanson Pharm
    • 12.12 Meidakang Huakang Pharmaceutical
    • 12.13 Shandong Kongfu Pharmaceutical
    • 12.14 J&J
    • 12.15 Takeda
    • 12.16 Amgen
    • 12.17 Bristol Myers Squibb
    • 12.18 Abbvie
    • 12.19 Seattle Genetics
    • 12.20 Karyopharm Therapeutics
    • 12.21 PDL BioPharma
    • 12.22 Roche
    • 12.23 Sumitomo
    • 12.24 Merck
    • 12.25 Biogen
    • 12.26 Schering-Plough
    • 12.27 Glaxo
    • 12.28 Chiron

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      In 2018, the global Targeted Drugs for Multiple Myeloma market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Targeted Drugs for Multiple Myeloma status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Targeted Drugs for Multiple Myeloma development in United States, Europe and China.

      The key players covered in this study
      Celgene
      SL Pharma
      Natco Pharma
      Intas Pharmaceuticals
      Indiabulls Pharmaceutical
      Cipla
      Glenmark Pharmaceuticals
      Dr Reddy's Laboratories
      Qilu Pharmaceutical
      Chia Tai-Tianqing
      Hanson Pharm
      Meidakang Huakang Pharmaceutical
      Shandong Kongfu Pharmaceutical
      J&J
      Takeda
      Amgen
      Bristol Myers Squibb
      Abbvie
      Seattle Genetics
      Karyopharm Therapeutics
      PDL BioPharma
      Roche
      Sumitomo
      Merck
      Biogen
      Schering-Plough
      Glaxo
      Chiron

      Market segment by Type, the product can be split into
      Immunomodulator
      Proteasome Inhibitors
      Histone Deacetylase Inhibitors (HDACI)
      Monoclonal Antibody
      Other

      Market segment by Application, split into
      Hospital
      Drug Center
      Clinic
      Other

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Targeted Drugs for Multiple Myeloma status, future forecast, growth opportunity, key market and key players.
      To present the Targeted Drugs for Multiple Myeloma development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Targeted Drugs for Multiple Myeloma are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now